| Julia Pansewicz, | |
|
165 Front St, Driggs, ID 83422-5445 | |
| (208) 716-2351 | |
| Not Available |
| Full Name | Julia Pansewicz |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 165 Front St, Driggs, Idaho |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336512607 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | TSLP-2786 (Idaho) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Julia Pansewicz, Po Box 881, Wilson, WY 83014-0881 Ph: (802) 233-3050 | Julia Pansewicz, 165 Front St, Driggs, ID 83422-5445 Ph: (208) 716-2351 |
News Archive
Argos Therapeutics today announced that, in an interim analysis of a Phase 2 trial, its Arcelis immunotherapy targeted at HIV, AGS-004, demonstrated a significant reduction in viral load and a delay in viral rebound kinetics during a 12-week antiretroviral treatment interruption (ARTI) when compared to pre-ART viral loads.
Some patients with advanced heart failure caused by cardiomyopathy, the deterioration of function of the heart muscle, are benefitting from a new recovery protocol at the University of Louisville and Jewish Hospital, a part of KentuckyOne Health.
In new data from a Phase III study in 345 children and adolescents (ages 5-17 years), patients with grass pollen allergic rhinoconjunctivitis treated with Merck's investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) showed a 26 percent greater improvement in the total combined score (daily symptom score and daily medication score), compared to patients receiving placebo
New research is calling for immediate safeguards and the study of a widely used method for repairing sewer-, storm-water and drinking-water pipes to understand the potential health and environmental concerns for workers and the public.
Sequella, a clinical-stage pharmaceutical company commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it has licensed Pfizer Inc's exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis.
› Verified 7 days ago
Ann Tomchak, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3872 South St, Driggs, ID 83422 Phone: 419-908-8668 | |
Kladuke Inc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 35 N 1st St, Driggs, ID 83422 Phone: 208-354-5775 | |
Jacqueline Lee Brown, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 30 N 1st E, Driggs, ID 83422 Phone: 208-716-2351 | |
Emily Erickson, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 616 W 3000 S, Driggs, ID 83422 Phone: 307-349-4332 | |
Karen Laduke, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 120 E Howard Ave, Driggs, ID 83422 Phone: 208-354-6333 | |
Ms. Jacquelyn Rae Seguin, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: High Peaks Health And Fitness, 50 Ski Hill Road, Driggs, ID 83422 Phone: 208-354-3128 |